Edition:
India

Stratec SE (SBSG.DE)

SBSG.DE on Xetra

62.00EUR
9:06pm IST
Change (% chg)

€-0.20 (-0.32%)
Prev Close
€62.20
Open
€62.20
Day's High
€62.50
Day's Low
€61.80
Volume
2,562
Avg. Vol
3,657
52-wk High
€77.10
52-wk Low
€43.55

Latest Key Developments (Source: Significant Developments)

Stratec Biomedical 9mth adj EBIT up at EUR 24.0 mln
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - STRATEC BIOMEDICAL AG ::9M SALES ROSE 19.6 PERCENT TO 151.1 MILLION EUR.‍OUTLOOK FOR 2017 FINANCIAL YEAR CONFIRMED​.‍ADJUSTED EBIT MARGIN OF 15.9% IN 9M|2017 (9M|2016: 14.6%)​.9MTH ADJUSTED EBIT GREW BY 30.4% FROM EUR 18.4 MILLION IN PREVIOUS YEAR TO EUR 24.0 MILLION IN 2017​.9MTH ‍ADJ CONSOLIDATED NET INCOME UP YEAR-ON-YEAR BY 22.1% TO EUR 18.6 MILLION.  Full Article

STRATEC Biomedical H1 net profit down 3.5 percent at 9.9 mln euros
Tuesday, 25 Jul 2017 

July 25 (Reuters) - STRATEC BIOMEDICAL AG :H1 SALES ROSE 29.1 PERCENT TO 100.7 MILLION EUR.H1 NET PROFIT FELL 3.5 PERCENT TO 9.9 MILLION EUR.NOT ISSUING ANY SPECIFIC STATEMENT CONCERNING ITS EXPECTATIONS FOR 2018.‍GROUP EBIT WAS EUR 12.9 MILLION IN FIRST HALF OF 2017, VERSUS 12.6 MILLION EUROS YEAR AGO​.2017 EBIT MARGIN IS EXPECTED TO BE AROUND 17%.‍FOR 2017 IS UPHOLDING ITS CURRENT SALES FORECAST, WHICH PROVIDES FOR FY SALES OF BETWEEN EUR 205 MILLION AND EUR 220 MILLION​.‍EXPECTS FY SALES TO SIGNIFICANTLY EXCEED LOWER END OF THIS RANGE​.  Full Article